85763-16-2

Usage

InChI:InChI=1/C16H12O4/c17-14(10-15(18)16(19)20)13-8-6-12(7-9-13)11-4-2-1-3-5-11/h1-9H,10H2,(H,19,20)

Upstream product

• 63656-27-9 4-Biphenyl-4-yl-2,4-dioxo-butyric acid methyl ester 
• 92-52-4 biphenyl 
• 92-91-1 biphenyl-4-acetaldehyde 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 1037816-85-5 5-((1,1'-biphenyl)-4-yl)-1H-pyrazole-3-carboxylic acid 

Relevant academic research and scientific papers

5-Aryl-1H-pyrazole-3-carboxylic acids as selective inhibitors of human carbonic anhydrases IX and XII

Inhibitory activity of a congeneric set of 23 phenyl-substituted 5-phenyl-pyrazole-3-carboxylic acids toward human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms I, II, IX and XII was evaluated by a stopped-flow CO2 hydrase assay. These compounds exerted a clear, selective inhibition of hCA IX and XII over hCAI and II, with Ki in two to one digit micromolar concentrations (4-50 μM). Derivatives bearing bulkier substituents in para-position of the phenyl ring inhibited hCA XII at one-digit micromolar concentrations, while derivatives having alkyl substituents in both ortho- and meta-positions inhibited hCA IX with Kis ranging between 5 and 25 μM. Results of docking experiments offered a rational explanation on the selectivity of these compounds toward CA IX and XII, as well as on the substitution patterns leading to best CA IX or CA XII inhibitors. By examining the active sites of these four isoforms with GRID generated molecular-interaction fields, striking differences between hCA XII and the other three isoforms were observed. The field of hydrophobic probe (DRY) appeared significantly different in CA XII active site, comparing to other three isoforms studied. To the best of our knowledge such an observation was not reported in literature so far. Considering the selectivity of these carboxylates towards membrane-associated over cytosolic CA isoforms, the title compounds could be useful for the development of isoform-specific non-sulfonamide CA inhibitors.

The identification and optimization of 2,4-diketobutyric acids as flap endonuclease 1 inhibitors

Flap endonuclease 1 (FEN1) is a key enzyme involved in base excision repair (BER), a primary pathway utilized by mammalian cells to repair DNA damage. In this report, we describe the identification and SAR of a series of 2,4-diketobutyric acid FEN1 inhibi

Inhibitors of Glycolic Acid Oxidase. 4-Substituted 2,4-Dioxobutanoic Acid Derivatives

Fourteen new 4-substituted 2,4-dioxobutanoic acids have been synthesized.These compounds, all of which contain lipophilic 4-substituents, are potent inhibitors in vitro of porcine liver glycolic acid oxidase.The I50 value of the two most potent representatives, 4-(4'-bromo-4-yl)-2,4-dioxobutanoic acid (8) and 4-thio>-4-yl>-2,4-dioxobutanoic acid (13) is 6 * 10-8 M.

2,4-Dioxo-4-substituted-1-butanoic acid derivatives useful in treating urinary tract calcium oxalate lithiasis

2,4-Dioxo-4-substituted-1-butanoic acid derivatives of the formula: STR1 where R is hydrogen or C1-4 alkyl; and L is a lipophilic group consisting essentially of: STR2 where R1 and R2 are each independently selected from the group consisting of (a) hydrogen; (b) C4-12 straight or branched chain alkyl; (c) C4-7 cycloalkyl; and (d) tetrahydronaphthyl; provided that R1 and R2 may not both be hydrogen; and when one of R1 or R2 is tetrahydronaphthyl, the other must be some other substituent; and that positions 2 and 6 of the substituted phenyl moiety may not be substituted; and STR3 where R1, and R2 have the same meaning as above except tetrahydronaphthyl; R3 is bromine, chlorine, or fluorine; m is 0 to 3; or a pharmaceutically acceptable salt thereof.